Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.

Mohammed A AlghamdiCarla P AmaroRichard Lee-YingHao-Wen SimHaider SamwiKelvin K ChanJennifer J KnoxYoo-Joung KoMina SwihaEugene BatuyongAdriana RomagninoWinson Y CheungVincent C Tamnull null

Published in: Cancer medicine (2020)

Starting HCC patients on a reduced dose of sorafenib compared to full dose may not compromise survival. Mean dose-intensity of sorafenib may also not affect survival.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
high intensity
chronic kidney disease
free survival
emergency department
clinical trial
peritoneal dialysis
prognostic factors
adverse drug